

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived
Ser57-Thr389
Accession # AAC25397

N-terminal Sequence Analysis Ser57 & Asp71

Predicted Molecular Mass 38 kDa

SPECIFICATIONS

SDS-PAGE 41-60 kDa, reducing conditions

Activity Measured by its ability to inhibit cell proliferation/survival assay using C3H10T1/2 mouse embryonic fibroblast cells.
The ED₅₀ for this effect is 1-5 µg/ml.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE with silver staining, under reducing conditions.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS, EDTA and CHAPS with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 100 µg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Mouse Wnt-2b (also known as Wnt-13) is a member of the large and highly conserved Wnt family of signaling molecules that have roles in pattern formation, cell fate decision, axon guidance, and tumor formation (1). Mouse Wnt-2b is 389 amino acids (aa) in length and includes a signal peptide (2). Mature mouse Wnt-2b has a predicted molecular mass of 38 kDa and shares 96% aa sequence identity with the human protein. Wnt-2b initiates B-catenin-mediated canonical signaling and is implicated in the development of the lung, kidney, liver, and eye, as well as being present in ovarian surface epithelial cells (3-8). Pathological expression of Wnt-2b in tumors is correlated with increased cell proliferation and decreased survival (9).

References:

1. Anastas, J.N. and R.T. Moon (2013) Nat. Rev. Cancer **13**:11.
2. Zakin, L.D. *et al.* (1998) Mech. Dev. **73**:107.
3. Goss, A.M. *et al.* (2009) Dev. Cell **17**:290.
4. Ricken, A. *et al.* (2002) Endocrinology **143**:2741.
5. Lin, Y. *et al.* (2001) Dev. Dyn. **222**:26.
6. Jasoni, C. *et al.* (1999) Dev. Dyn. **215**:215.
7. Ober, E.A. *et al.* (2006) Nature **442**:688.
8. Kubo, F. *et al.* (2005) Development **132**:2759.
9. Kobayashi, M. *et al.* (2012) Exp. Ther. Med. **3**:952.